West Palm Beach, FL – According to filings with the U.S. Securities and Exchange Commission, EXUMA Biotech is raising $18,950,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Gregory Frost played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About EXUMA Biotech

EXUMA Biotech is a clinical-stage biotechnology company discovering and developing Chimeric Antigen Receptor (CAR)-T cell products for solid tumors. CAR-T cell therapy has already delivered remarkable on-target responses to certain hematological malignancies through a complex manufacturing process. Through our logic gated CAR-T platform, we are taking cellular therapies to the next step by harnessing the power of the immune system to target some of the most challenging solid tumor malignancies, and building CAR-T delivery platforms that may enable more patients to access cellular therapies in the future.

To learn more about EXUMA Biotech, visit http://exumabio.com/

Contact:
Gregory Frost, Chief Executive Officer
561-660-5049
gfrost@exumabio.com
https://www.linkedin.com/in/gregory-frost-055a421/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved